Bioethical and clinical dilemmas of direct-to-consumer personal genomic testing: The problem of misattributed equivalence

Charis Eng, Richard R Sharp

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

A number of for-profit companies now provide personal genomic testing services to clients directly, without input from a physician or other health care provider, and the results of these tests include predictions about a broad spectrum of disease risks and traits. Validated clinical genetic testing and direct-to-consumer (DTC) genomic tests differ substantially in their reliability and usefulness, raising many clinical, ethical, and societal challenges, which are discussed in this Commentary. Of special concern is the problem of misattributed equivalence, which occurs when a patient or physician mistakenly views alternative methods of genetic evaluation as equivalent in their results and analytic rigor. Despite the many challenges raised by DTC genomic testing, we are reminded that commercial interests have sometimes acted as a disruptive force or technology that drives nonconventional approaches to difficult problems.

Original languageEnglish (US)
JournalScience Translational Medicine
Volume2
Issue number17
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Physicians
Genetic Testing
Health Personnel
Technology
Direct-To-Consumer Screening and Testing

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{2cf8734734574d158b2d57948ebdf555,
title = "Bioethical and clinical dilemmas of direct-to-consumer personal genomic testing: The problem of misattributed equivalence",
abstract = "A number of for-profit companies now provide personal genomic testing services to clients directly, without input from a physician or other health care provider, and the results of these tests include predictions about a broad spectrum of disease risks and traits. Validated clinical genetic testing and direct-to-consumer (DTC) genomic tests differ substantially in their reliability and usefulness, raising many clinical, ethical, and societal challenges, which are discussed in this Commentary. Of special concern is the problem of misattributed equivalence, which occurs when a patient or physician mistakenly views alternative methods of genetic evaluation as equivalent in their results and analytic rigor. Despite the many challenges raised by DTC genomic testing, we are reminded that commercial interests have sometimes acted as a disruptive force or technology that drives nonconventional approaches to difficult problems.",
author = "Charis Eng and Sharp, {Richard R}",
year = "2010",
doi = "10.1126/scitranslmed.3000214",
language = "English (US)",
volume = "2",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "17",

}

TY - JOUR

T1 - Bioethical and clinical dilemmas of direct-to-consumer personal genomic testing

T2 - The problem of misattributed equivalence

AU - Eng, Charis

AU - Sharp, Richard R

PY - 2010

Y1 - 2010

N2 - A number of for-profit companies now provide personal genomic testing services to clients directly, without input from a physician or other health care provider, and the results of these tests include predictions about a broad spectrum of disease risks and traits. Validated clinical genetic testing and direct-to-consumer (DTC) genomic tests differ substantially in their reliability and usefulness, raising many clinical, ethical, and societal challenges, which are discussed in this Commentary. Of special concern is the problem of misattributed equivalence, which occurs when a patient or physician mistakenly views alternative methods of genetic evaluation as equivalent in their results and analytic rigor. Despite the many challenges raised by DTC genomic testing, we are reminded that commercial interests have sometimes acted as a disruptive force or technology that drives nonconventional approaches to difficult problems.

AB - A number of for-profit companies now provide personal genomic testing services to clients directly, without input from a physician or other health care provider, and the results of these tests include predictions about a broad spectrum of disease risks and traits. Validated clinical genetic testing and direct-to-consumer (DTC) genomic tests differ substantially in their reliability and usefulness, raising many clinical, ethical, and societal challenges, which are discussed in this Commentary. Of special concern is the problem of misattributed equivalence, which occurs when a patient or physician mistakenly views alternative methods of genetic evaluation as equivalent in their results and analytic rigor. Despite the many challenges raised by DTC genomic testing, we are reminded that commercial interests have sometimes acted as a disruptive force or technology that drives nonconventional approaches to difficult problems.

UR - http://www.scopus.com/inward/record.url?scp=77952964651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952964651&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3000214

DO - 10.1126/scitranslmed.3000214

M3 - Article

C2 - 20371476

AN - SCOPUS:77952964651

VL - 2

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 17

ER -